ArticleTherapeutic advances in endocrinology and metabolism2020
Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications.
Article in Therapeutic advances in endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Fatty liver index (FLI): more than a marker of hepatic steatosis.Journal of physiology and biochemistry · 2024Pooled it
- Anti-Obesity Effects of a Collagen with Low Digestibility and High Swelling Capacity: A Human Randomized Control Trial.Nutrients · 2024Trial
- A nutrition-focused model for predicting postoperative complications in locally advanced gastric cancer after neoadjuvant chemotherapy: a retrospective cohort study.BMC gastroenterology · 2026Article
- Association of Composite Metabolic Indices With Incident Carotid Plaque: A Chinese Cohort Study.Journal of the American Heart Association · 2026Article
- Association Between Serum Vitamin D Levels and Visceral Adipose Tissue in Older Adults in Iran: A Cross-Sectional Study From the Amirkola Health and Aging Project.Clinical nutrition research · 2025Article
- Impact of obesity and diabetes on colorectal cancer in Saudi Arabia is associated with liver γ‑glutamyl transferase abnormality.Experimental and therapeutic medicine · 2025Article
- Article
- The association between triglyceride-glucose index and hyperferritinemia in patients with type 2 diabetes mellitus.Hormones (Athens, Greece) · 2023Article
- Carbonylated Proteins as Key Regulators in the Progression of Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2023Article
- The association of dietary insulin load and dietary insulin index with body composition among professional soccer players and referees.BMC sports science, medicine & rehabilitation · 2023Article
- Health associations of liver enzymes and inflammatory scores with urinary citrus flavonoid metabolites.Food & function · 2023Article
- Relationship between Insulin Resistance Risk Scales and Non-Alcoholic Fatty Liver Disease and Liver Fibrosis Scales in 219,477 Spanish Workers.Metabolites · 2022Article
- Association between triglyceride-glucose index and nonalcoholic fatty liver disease in type 2 diabetes mellitus.BMC endocrine disorders · 2022Article
- Triglyceride-glucose index and common carotid artery intima-media thickness in patients with ischemic stroke.Cardiovascular diabetology · 2022Article
- Lower Visceral Fat Area in Patients with Type 2 Diabetic Peripheral Neuropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Construction of a Personalized Insulin Resistance Risk Assessment Tool in Xinjiang Kazakhs Based on Lipid- and Obesity-Related Indices.Risk management and healthcare policy · 2022Article
- Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study.European journal of nutrition · 2021Article
- Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS).
methodsA cross-sectional study was performed including 326 participants with MetS (55-75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT (
resultsSubjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1-10.7) had a positive association with HOMA-IR [
conclusionsA disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.